Table 1 Patients characteristics
No AR group n = 64 | Early-AR group n = 22 | Late-AR group n = 4 | P-value | |
|---|---|---|---|---|
Age (years), mean ± SD | 40.4 ± 16.7 | 41.9 ± 12.7 | 38.5 ± 15.1 | 0.896 |
Sex (male/female) | 28/36 | 13/9 | 0/4 | 0.079 |
Body weight (kg), mean ± SD | 45.3 ± 13.3 | 50.8 ± 15.4 | 42.3 ± 9.2 | 0.227 |
Body mass index (kg/m2), mean ± SD | 17.9 ± 3.3 | 19.4 ± 4.0 | 17.2 ± 2.8 | 0.195 |
Indication for transplant, n (%) | ||||
Interstitial pneumonia | 29 (45) | 9 (41) | 2 (50) | 0.913 |
BO after HSCT | 9 (14) | 4 (18) | 0 (0) | 0.627 |
Pulmonary hypertension | 6 (9) | 1 (5) | 1 (25) | 0.403 |
Others | 20 (32) | 8 (36) | 1 (25) | 0.862 |
LT type (LDLT/DDLT) | 16/48 | 7/15 | 1/3 | 0.820 |
LT type (Bilateral/Single) | 41/23 | 19/3 | 3/1 | 0.140 |
Baseline aspartate aminotransferase (IU/L), mean ± SD | 25.2 ± 17.9 | 19.2 ± 6.7 | 27.0 ± 7.7 | 0.283 |
Baseline alanine aminotransferase (IU/L), mean ± SD | 18.0 ± 12.0 | 16.0 ± 7.9 | 23.8 ± 10.7 | 0.425 |
Baseline total bilirubin (mg/dL), mean ± SD | 0.6 ± 0.3 | 0.7 ± 0.3 | 0.4 ± 0.1 | 0.266 |
Baseline serum creatinine (mg/dL), mean ± SD | 0.6 ± 0.2 | 0.6 ± 0.2 | 0.7 ± 0.3 | 0.166 |
Baseline eGFR (mL/min/1.73m2), mean ± SD | 143.2 ± 103.2 | 135.3 ± 172.9 | 113.6 ± 78.9 | 0.882 |
Baseline albumin (g/dL), mean ± SD | 3.9 ± 0.5 | 3.9 ± 0.5 | 3.5 ± 0.7 | 0.217 |
With diabetes mellitus, n (%) | 3 (5) | 0 (0) | 0 (0) | 0.532 |
With dialysis, n (%) | 3 (5) | 0 (0) | 0 (0) | 0.532 |
Tacrolimus use before LT, n (%) | 8 (13) | 5 (23) | 2 (50) | 0.101 |
Anti HLA antibody ( +) before LT, n (%) | 6 (9) | 0 (0) | 1 (25) | 0.154 |
Operative time (h), mean ± SD | 7.8 ± 2.9 | 9.5 ± 2.6 | 7.8 ± 2.4 | 0.069 |
Operative blood loss (mL), mean ± SD | 2803.0 ± 4155.0 | 4765.2 ± 6445.7 | 2061.5 ± 1233.0 | 0.233 |
Length of ICU stay (days), mean ± SD | 12.8 ± 7.7 | 18.4 ± 5.3 | 15.0 ± 6.8 | 0.009 |
Length of hospital stays from postoperative to discharge (days), mean ± SD | 63.2 ± 27.9 | 85.9 ± 61.5 | 117.0 ± 41.9 | 0.006 |
Concomitant use of ITCZ, n (%) | 63 (98) | 21 (95) | 4 (100) | 0.682 |
Discontinuation of MMF, n (%) | 6 (9) | 2 (9) | 0 (0) | 0.814 |
Infection after LT, n (%) | 10 (16) | 5 (22) | 3 (75) | 0.014 |